- Home
- KURA vs ATTO Comparison
KURA vs ATTO Comparison
Compare KURA & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | ATTO |
|---|---|---|
| Founded | 2014 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | KURA | ATTO |
|---|---|---|
| Price | $9.83 | $14.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $31.85 | ★ $42.20 |
| AVG Volume (30 Days) | ★ 1.6M | 411.9K |
| Earning Date | 11-03-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $42.46 | N/A |
| Revenue Next Year | $116.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $7.36 | $14.44 |
| 52 Week High | $13.90 | $28.00 |
Technical Indicators
Market Signals| Indicator | KURA | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 31.67 | 31.22 |
| Support Level | $8.45 | N/A |
| Resistance Level | $11.32 | $18.38 |
| Average True Range (ATR) | 0.42 | 1.18 |
| MACD | -0.06 | -0.34 |
| Stochastic Oscillator | 13.92 | 10.16 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.